Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ6 | P48051 | 3/20 | 0.46 |
| ▸ | KCNJ5 | P48544 | 3/20 | 0.46 |
| ▸ | KCNJ3 | P48549 | 3/20 | 0.46 |
| ▸ | CFTR | P13569 | 3/20 | 0.42 |
| ▸ | SPR | P35270 | 1/20 | 0.38 |
| ▸ | PDE7A | Q13946 | 4/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | F10 | P00742 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL287415 | 0.89 | NOTUM (0.41) | KCNJ6KCNJ5KCNJ3TSHR | |
| SCHEMBL18412894 | 0.88 | KCNJ6 (0.43) | KCNJ6KCNJ5KCNJ3CFTRSPR | |
| SCHEMBL25400204 | 0.86 | KCNJ3 (0.45) | KCNJ6KCNJ5KCNJ3ALDH1A1 | |
| SCHEMBL9682398 | 0.86 | KCNJ3 (0.43) | KCNJ6KCNJ5KCNJ3TSHR | |
| Hydrochloric Acid SCHEMBL9681843 | 0.84 | KCNJ3 (0.42) | KCNJ6KCNJ5KCNJ3TSHR | |
| SCHEMBL18394940 | 0.82 | KCNJ6 (0.44) | KCNJ6KCNJ5KCNJ3ALDH1A1 | |
| SCHEMBL17287032 | 0.79 | F10 (0.41) | KCNJ6KCNJ5KCNJ3CFTRSPR | |
| SCHEMBL22851671 | 0.78 | KCNJ6 (0.41) | KCNJ6KCNJ5KCNJ3CFTRSPR | |
| SCHEMBL15832226 | 0.77 | SIGMAR1 (0.43) | KCNJ6KCNJ5KCNJ3TGFBR1ALDH1A1 | |
| SCHEMBL18161176 | 0.75 | KCNJ6 (0.40) | KCNJ6KCNJ5KCNJ3CFTRSPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570675-B2 | Boronic acid compounds | LG CHEM, LTD. (KR) | 2026-03-10 | — | — | US | disclosed |
| US-20240101579-A1 | BORONIC ACID COMPOUNDS | LG CHEM, LTD. (KR) | 2024-03-28 | — | — | US | disclosed |
| EP-4242213-A1 | BORONIC ACID COMPOUND | Lg Chem, Ltd. (KR) | 2023-09-13 | — | — | EP | disclosed |
| CN-116568310-A | Boric acid compounds | 株式会社LG化学 | 2023-08-08 | — | — | CN | disclosed |
| US-20220259193-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2022-08-18 | — | — | US | disclosed |
| US-20220259193-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2022-08-18 | — | — | US | disclosed |
| WO-2022123530-A1 | BORONIC ACID COMPOUND | 주식회사 엘지화학 | 2022-06-16 | — | — | WO | disclosed |
| CN-114269340-A | KCNT1 inhibitors and methods of use | 普拉克西斯精密药物股份有限公司 | 2022-04-01 | — | — | CN | disclosed |
| EP-3962481-A1 | KCNT1 INHIBITORS AND METHODS OF USE | Praxis Precision Medicines, Inc. (US) | 2022-03-09 | — | — | EP | disclosed |
| WO-2020227101-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2020-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570675-B2 | Boronic acid compounds | PSMB6, PSMB3, PSMB2 | KCNJ6 3602/4885KCNJ5 4235/4885KCNJ3 3836/4885 |
| US-20240101579-A1 | BORONIC ACID COMPOUNDS | PSMB11, PSMB1, BACH1 | KCNJ6 3551/4885KCNJ5 3584/4885KCNJ3 4042/4885 |
| US-20220259193-A1 | KCNT1 INHIBITORS AND METHODS OF USE | KCNT1, KCNT2, KCNQ2 | KCNJ6 40/4885KCNJ5 41/4885KCNJ3 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.